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Supplemental Experimental Procedures and Results 
This supplementary material includes kinetic and synthetic data.  The kinetic 
experiments include: (i) representative 50S modified fragment assay results, (ii) primary 
data to demonstrate the independence of reaction rate on DMSO concentration within 
70S ribosomes, and (iii) representative 70S initiation complex assay results.  A 
complete synthetic description and chemical characterization for the various puromycin 
derivatives used in this study are also described.   
PRIMARY KINETIC DATA  
i.  Representative 50S data 
Cytidine-puromycin (CPmn) derivatives were reacted with 32P 5'-end labeled 
CCA-pcb (P-site substrate) and 50S ribosomes at pH 8.5.  The reaction substrates and 
products were separated under low-pH PAGE conditions to minimize background CCA-
pcb hydrolysis (Figure S1A).  The reaction rate (kpep) was determined by plotting the 
fraction unreacted versus time (Figure S1B). 
 
ii.  Effect of DMSO on 70S reaction rate  
 Several of the derivatives were not sufficiently soluble in water to reach a 
saturating concentration in the 70S assay.  DMSO was added to the reactions to 
increase reagent solubility.  A DMSO concentration of 60% was found to be sufficient to 
solubilize the puromycin derivatives without significantly affecting the reaction rate.  
Puromycin (Pmn) was reacted with f[3H]Met-tRNAfMet in 70S initiation complexes at pH 
8.5 using a quench-flow apparatus in the presence of 0% and 60% DMSO.  After 
quenching and extraction, dipeptide formation was quantitated by radioactive counting 
and the data fit as described in Materials and Methods (Figures S2A and S2B). 60% 
DMSO does not affect kpep for the 70S puromycin reaction (12 sec-1 without DMSO, 13 
sec-1 with DMSO) and only slightly increases the apparent KM (2.5 mM without DMSO, 
6.1 mM with DMSO) (Figures S2C and S2D).  
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iii.  Representative 70S data 
 Puromycin (Pmn) derivatives were reacted with f[3H]Met-tRNAfMet in the 70S 
initiation complex assay as described above.   
 
Figure S1.  CPmn Derivative Rate Constant (kpep) Determination with the 50S Modified 
Fragment Assay 
(A) Representative polyacrylamide gel (12%) used to resolve unreacted *CCA-pcb from 
reacted *CCA.  (B) Representative data obtained from PAGE phosphorimager 










Figure S2.  DMSO Effect on fMetPmn Formation for the 70S Initiation Complex (IC) 
Assay 
Quench-flow assays were performed using 70S initiation complexes (0.1 μM) in buffer B 
(see Materials and Methods) at 37 ˚C and Pmn concentrations of 0.5 mM (●), 1 mM (■), 
2 mM (♦), 4 mM (○), and 8 mM (□).  (A) Time courses in the absence of DMSO.  (B)  
Time courses in the presence of 60% DMSO.  kobs values for individual curves were 
obtained by single-exponential fitting.  (C) Concentration dependence of kobs in the 
absence of DMSO. (D) Concentration dependence of kobs in the presence of 60% 
DMSO.  Fitting the data to a two-step model with a reversible binding step followed by 











Figure S3.  Rate Constant of Reaction (kpep) and Apparent Affinity to the Ribosome (KM) 
of Pmn Derivatives in the 70S Initiation Complex Assay 
Representative time courses (A, C, E) and kobs concentration dependencies (B, D, F) 
for: (A)&(B) Puromycin(β,β-F-Phe); (C)&(D) Puromycin(3,4-Cl-Phe); and (E)&(F) 
Puromycin(4-CH3-Phe).  All data were fit as above. 
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SYNTHETIC SCHEME 
Puromycin (Pmn) derivatives were prepared by solution phase chemistry (Scheme 1 a) 
and Cytidine-puromycin (CPmn) derivatives were prepared by combining solution phase 
synthesis and solid phase synthesis (scheme 1 a-e).  After activation of N-Fmoc 
protected amino-acids by cyanuric fluoride, the corresponding acyl fluorides 1a-g were 
coupled to puromycin aminonucleoside to generate the puromycin derivatives 2a-g in 
good yield (method 1, 87 – 99%).  Another coupling method using N-
hydroxysuccinimide (SuOH) and 1-[3-(dimethylamino)propyl]-3-ethylcarbodiimide 
hydrochloride (EDCI) was also used.  In this case, nucleosides analogs 2h-j were 
obtained in moderate yield (method 2, 85 – 87%).  For Pmn derivatives, nucleoside 
analogs 2a-j  were deprotected to produce the final compound .  For CPmn derivatives, 
nucleoside analogs 2a-j  were protected at the 5’-position by the acid-labile DmTr 
protecting group (compounds 3a-j) and then attached to the succinate linker at the 2’-
position.  The resulting succinate derivatives 4a-j were derivatized to the polymer 
support and used in solid phase synthesis.  The protected CPmn derivatives were 
cleaved from the support, deprotected and purified by reverse HPLC to produce pure 
CPmn analogues 5a-j. 















































































R = CH2P he- (2,4-Cl) (5b)
R = CH2P he- (2-NO2 ) (5c)
R = CH2P he- (2-F) (5d)
R = CH2P he- (3,4-F)  (5e)
R = CH2 P he- (2- CF 3)  ( 5f )
R = CH2 P he- (2,3 ,4 ,5 ,6-F) (5g)
R = CH2 P he- (4- CH 3 ) (5h)
R = CH2 P he- (4- NH 2 ) (5 i)
R = CH2 P he- (4- CF 3)  ( 5j)  
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Scheme 1: (a) method 1: acyl fluoride 1a-g, cyanuric fluoride, Pyridine, DMF, RT, 3h, 87 
– 99%. method 2: N-Fmoc-amino-acid, SuOH, EDCI, DMF, RT, 24h, 85 – 87%. (b) 
DmTrCl, Pyridine, NEt3, RT, 3h, 40 – 79%. (c) succinic anhydride, DMAP, Pyridine, RT, 
overnight, 62 – 85%. (d) Amino derivatized Primer Support, EDCI, DMAP, Pyridine, 
NEt3, RT. (d) solid phase synthesis. 
 
METHODS 
All reactions were monitored by thin-layer chromatography (TLC) using E. Merck silica 
gel 60 F254 precoated plates (0.25 mm).  Flash chromatography was performed with 
the indicated solvent system using Silicycle 0.040-0.060 mm silica gel.  NMR spectra 
were measured on Brucker Avance DPX-400 and Brucker Avance DPX-500 
spectrometers.  1H and 13C NMR chemical shifts were recorded using tetramethylsilane 
as an internal standard and 19F NMR chemical shifts were recorded using 
trichlorofluoromethane as an internal standard.  Mass spectra were collected on Waters 
Micromass LCT and Waters Micromass ZQ mass spectrometers.  Chemicals and 
anhydrous solvents were used as received from commercial suppliers.  Protected 
amino-acids and puromycin aminonucleoside were purchased from Sigma-Aldrich or 
CSPS pharmaceuticals.   
 
General Procedure for the Preparation of Acyl Fluoride Derivatives 1a-g 
In a 50 ml round bottom flask containing the N-(9-fluorenylmethoxycarbonyl)-amino acid 
(1 eq), anhydrous dichloromethane, anhydrous pyridine (1.5 eq), and cyanuric fluoride 
(3 eq) were added under argon.  The solution was stirred 24 h at room temperature, 
then diluted into dichloromethane (60 ml) and extracted with cold water (3 x 25 ml). The 
organic layer was dried with anhydrous MgSO4, filtered and concentrated. The residue 
was recrystallized from dichloromethane/hexane to give the corresponding acyl fluoride 
derivatives 1a-g. 
 
N-(9-Fluorenylmethoxycarbonyl)-L-3,4-dichlorophenylalanyl Fluoride 1a.   Isolated in 
79% yield (395 mg), starting from N-(9-Fluoroenylmethoxycarbonyl)-3,4-
dichlorophenylalanine (500 mg, 1.095 mmol), anhydrous dichloromethane (14 ml), 
anhydrous pyridine (133 μl, 1.643 mmol), cyanuric fluoride (445 mg, 3.285 mmol): 1H 
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NMR (400 MHz, DMSO-d6): 8.19 (d, 1H, 3JHH = 7.6 Hz), 7.93 (d, 2H, 3JHH = 7.5 Hz), 
7.63 (m, 3H), 7.58 (d, 1H, 3JHH = 8.2 Hz), 7.45 (t, 2H, 3JHH = 7.4 Hz), 7.34 (q, 2H, 3JHH = 
6.4 Hz), 7.25 (dd, 1H, 4JHH = 1.9 Hz, 3JHH = 8.2 Hz), 4.69 (m, 1H), 4.43 (dd, 1H, 3JHH = 
6.7 Hz, 2JHH = 10.6 Hz), 4.34 (dd, 1H, 3JHH = 6.7 Hz, 2JHH = 10.5 Hz), 4.24 (t, 1H, 3JHH = 
6.5 Hz), 3.21 (dd, 1H, 3JHH = 4.6 Hz, 2JHH = 13.8 Hz), 3.02 (dd, 1H, 3JHH = 10.6 Hz, 2JHH = 
13.7 Hz). 19F NMR (376 MHz, DMSO-d6): 29.45 (s, 1F). 13C NMR (125 MHz, DMSO-
d6): 164.12 (d, 1JCF = 372.6 Hz), 158.03, 145.74, 145.72, 142.92, 142.90, 139.94, 
133.48, 132.97, 132.53, 131.92, 131.68, 129.81, 129.21, 129.17, 127.20, 127.13, 
122.31, 67.96, 55.62 (d, 2JCF = 53.1 Hz), 48.73, 36.21 
 
N-(9-Fluorenylmethoxycarbonyl)-L-2,4-dichlorophenylalanyl Fluoride 1b. Isolated in 
88% yield (445 mg), starting from N-(9-Fluoroenylmethoxycarbonyl)-2,4-
dichlorophenylalanine (500 mg, 1.095 mmol), anhydrous dichloromethane (14 ml), 
anhydrous pyridine (133 μl, 1.643 mmol), cyanuric fluoride (445 mg, 3.285 mmol): 1H 
NMR (400 MHz, DMSO-d6): 7.98 (d, 1H, 3JHH = 7.6 Hz), 7.68 (d, 2H, 3JHH = 7.5 Hz), 
7.41 (m, 3H), 7.21 (t, 3H, 3JHH = 7.4 Hz), 7.12 (m, 3H), 4.38 (m, 1H), 4.21 (dd, 1H, 3JHH 
= 6.6 Hz, 2JHH = 10.5 Hz), 4.11 (dd, 1H, 3JHH = 6.7 Hz, 2JHH = 10.5 Hz), 3.99 (t, 1H, 3JHH 
= 6.5 Hz), 3.06 (dd, 1H, 3JHH = 5.0 Hz, 2JHH = 14.0 Hz), 2.94 (dd, 1H, 3JHH = 10.3 Hz, 
2JHH = 13.9 Hz). 19F NMR (376 MHz, DMSO-d6): 29.15 (s, 1F). 13C NMR (100 MHz, 
DMSO-d6): 162.17 (d, 1JCF = 372.2 Hz), 156.24, 143.96, 143.92, 141.13, 141.11, 
134.71, 133.51, 133.48, 132.92, 129.14, 128.02, 127.72, 127.42, 127.39, 125.43, 
125.36, 120.52, 66.18, 52.48 (d, 2JCF = 53.3 Hz), 46.91, 32.83. 
 
N-(9-Fluorenylmethoxycarbonyl)-L-2-nitrophenylalanyl fluoride 1c. Isolated in 95% yield 
(480 mg), starting from N-(9-Fluoroenylmethoxycarbonyl)-L-2-nitrophenylalanine (500 
mg, 1.156 mmol), anhydrous dichloromethane (15 ml), anhydrous pyridine (140 μl, 
1.734 mmol), cyanuric fluoride (470 mg, 3.468 mmol): 1H NMR (400 MHz, CDCl3): 8.02 
(d, 1H, 3JHH = 8.1 Hz), 7.75 (d, 2H, 3JHH = 7.5 Hz), 7.25 – 7.56 (m, 10H), 5.53 (d, 1H, 
3JHH = 8.1 Hz), 4.48 (m, 1H), 4.35 (m, 1H), 4.15 (t, 1H, 3JHH = 6.7 Hz), 3.61 (dd, 1H, 3JHH 
= 5.3 Hz, 2JHH = 13.7 Hz), 3.37 (dd, 1H, 3JHH = 9.5 Hz, 2JHH = 13.6 Hz). 19F NMR (376 
MHz, CDCl3): 30.91 (s, 1F). 13C NMR (100 MHz, CDCl3): 161.37 (d, 1JCF = 370.4 Hz), 
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155.57, 149.43, 143.49, 143.44, 141.30, 133.67, 132.91, 130.40, 128.94, 127.82, 
127.10, 125.45, 125.00, 124.94, 120.03, 67.42, 53.56 (d, 2JCF = 58.8 Hz), 46.95, 34.16. 
 
N-(9-Fluorenylmethoxycarbonyl)-L-2-fluorophenylalanyl fluoride 1d. Isolated in 95% 
yield (480 mg), starting from N-(9-Fluoroenylmethoxycarbonyl)-L-2-fluorophenylalanine 
(500 mg, 1.233 mmol), anhydrous dichloromethane (16 ml), anhydrous pyridine (150 μl, 
1.849 mmol), cyanuric fluoride (500 mg, 3.699 mmol): 1H NMR (400 MHz, DMSO-d6): 
8.24 (d, 1H, 3JHH = 7.5 Hz), 7.90 (d, 2H, 3JHH = 7.5 Hz), 7.64 (t, 2H, 3JHH = 6.7 Hz), 7.43 
(t, 2H, 3JHH = 7.4 Hz), 7.33 (m, 4H), 7.15 (m, 2H), 4.57 (m, 1H), 4.40 (dd, 1H, 3JHH = 6.9 
Hz, 2JHH = 10.4 Hz), 4.31 (dd, 1H, 3JHH = 6.7 Hz, 2JHH = 10.4 Hz), 4.21 (t, 1H, 3JHH = 6.6 
Hz), 3.21 (dd, 1H, 3JHH = 5.4 Hz, 2JHH = 14.0 Hz), 3.11 (dd, 1H, 3JHH = 9.9 Hz, 2JHH = 
13.7 Hz). 19F NMR (376 MHz, DMSO-d6): 29.79 (s, 1F), -118.07 (s, 1F). 13C NMR (100 
MHz, CDCl3): 161.76 (d, 1JCF = 344.0 Hz), 161.14 (d, 1JCF = 272.0 Hz), 143.54, 141.29, 
131.52 (d, 3JCF = 4.0 Hz), 129.77 (d, 3JCF = 8.0 Hz), 127.79, 127.09, 125.00, 124.67 (d, 
4JCF = 4.0 Hz), 121.60 (d, 2JCF = 16.0 Hz), 120.03, 115.73 (d, 2JCF = 22.0 Hz), 67.40, 
53.13 (d, 2JCF = 60.0 Hz), 47.00, 30.54. 
 
N-(9-Fluorenylmethoxycarbonyl)-L-3,4-difluorophenylalanyl fluoride 1e. Isolated in 97% 
yield (490 mg), starting from N-(9-Fluoroenylmethoxycarbonyl)-L-3,4-
difluorophenylalanine (500 mg, 1.180 mmol), anhydrous dichloromethane (15 ml), 
anhydrous pyridine (150 μl, 1.770 mmol), cyanuric fluoride (480 mg, 3.540 mmol): 1H 
NMR (400 MHz, DMSO-d6): 8.16 (d, 1H, 3JHH = 7.5 Hz), 7.90 (d, 2H, 3JHH = 7.5 Hz), 
7.62 (d, 2H, 3JHH = 7.3 Hz), 7.29 – 7.44 (m, 6H), 7.08 (m, 1H), 4.63 (m, 1H), 4.42 (dd, 
1H, 3JHH = 6.8 Hz, 2JHH = 10.6 Hz), 4.33 (dd, 1H, 3JHH = 6.6 Hz, 2JHH = 10.5 Hz), 4.21 (t, 
1H, 3JHH = 6.5 Hz), 3.17 (dd, 1H, 3JHH = 4.8 Hz, 2JHH = 13.9 Hz), 2.99 (dd, 1H, 3JHH = 
10.5 Hz, 2JHH = 13.8 Hz). 19F NMR (376 MHz, DMSO-d6): 30.08 (s, 1F), -138.98 (d, 1F, 
3JFF = 22.4 Hz), -141.50 (d, 1F, 3JFF = 22.3 Hz). 13C NMR (100 MHz, DMSO-d6): 162.02 
(d, 1JCF = 372.8 Hz), 155.86, 149.05 (dd, 2JCF = 12.5 Hz, 1JCF = 244.9 Hz), 148.44 (dd, 
2JCF = 12.5 Hz, 1JCF = 245.1 Hz), 143.55, 140.75, 140.73, 134.28 (dd, 4JCF = 4.0 Hz, 3JCF 
= 5.7 Hz), 127.64, 127.01, 126.97, 126.18 (dd, 4JCF = 3.2 Hz, 3JCF = 6.3 Hz), 125.03, 
124.96, 120.14, 118.19 (d, 2JCF = 17.0 Hz), 117.18 (d, 2JCF = 16.9 Hz), 65.72, 53.66 (d, 
2JCF = 52.9 Hz), 46.54, 34.11. 
 9 
 
N-(9-Fluorenylmethoxycarbonyl)-L-2-trifluoromethylphenylalanyl fluoride 1f. Isolated in 
95% yield (480 mg), starting from N-(9-Fluoroenylmethoxycarbonyl)-L-2-
trifluoromethylphenylalanine (500 mg, 1.097 mmol), anhydrous dichloromethane (15 
ml), anhydrous pyridine (133 μl, 1.645 mmol), cyanuric fluoride (445 mg, 3.291 mmol): 
1H NMR (400 MHz, DMSO-d6): 8.29 (d, 1H, 3JHH = 7.7 Hz), 7.91 (d, 2H, 3JHH = 7.5 Hz), 
7.73 (d, 1H, 3JHH = 7.7 Hz), 7.65 (t, 2H, 3JHH = 6.6 Hz), 7.60 (t, 1H, 3JHH = 7.3 Hz), 7.49 
(m, 2H), 7.43 (t, 2H, 3JHH = 7.4 Hz), 7.33 (q, 2H, 3JHH = 6.9 Hz), 4.59 (m, 1H), 4.41 (dd, 
1H, 3JHH = 6.7 Hz, 2JHH = 10.5 Hz), 4.33 (dd, 1H, 3JHH = 6.6 Hz, 2JHH = 10.5 Hz), 4.21 (t, 
1H, 3JHH = 6.6 Hz), 3.35 (m, 1H), 3.23 (dd, 1H, 3JHH = 10.1 Hz, 2JHH = 14.1 Hz). 19F NMR 
(376 MHz, DMSO-d6): 29.45 (s, 1F), -57.97 (s, 3F). 13C NMR (100 MHz, DMSO-d6): 
161.89 (d, 1JCF = 372.2 Hz), 155.92, 143.61, 140.80, 140.79, 134.71, 132.45, 132.26, 
127.71, 127.66, 127.55 (q, 2JCF = 32.1 Hz), 127.11, 127.07, 125.97 (q, 3JCF = 5.6 Hz), 
125.10, 125.05, 124.46 (q, 1JCF = 273.9 Hz), 120.20, 65.90, 53.53 (d, 2JCF = 53.6 Hz), 
46.56, 31.88. 
 
N-(9-Fluorenylmethoxycarbonyl)-L-pentafluorophenylalanyl fluoride 1g. Isolated in 30% 
yield (150 mg), starting from N-(9-Fluoroenylmethoxycarbonyl)-L-
pentafluorophenylalanine (500 mg, 1.047 mmol), anhydrous dichloromethane (13.5 ml), 
anhydrous pyridine (130 μl, 1.570 mmol), cyanuric fluoride (425 mg, 3.141 mmol): 1H 
NMR (400 MHz, DMSO-d6): 8.22 (d, 1H, 3JHH = 7.6 Hz), 7.90 (d, 2H, 3JHH = 7.5 Hz), 
7.64 (t, 2H, 3JHH = 7.1 Hz), 7.43 (t, 2H, 3JHH = 7.4 Hz), 7.32 (t, 2H, 3JHH = 7.4 Hz), 4.66 
(m, 1H), 4.37 (m, 2H), 4.21 (t, 1H, 3JHH = 6.6 Hz), 3.25 (m, 2H). 19F NMR (376 MHz, 
DMSO-d6): 28.41 (s, 1F), -141.87 (dd, 2F, 4JFF = 7.6 Hz, 3JFF = 23.6 Hz), -156.58 (t, 1F, 
3JFF = 22.3 Hz), -163.15 (dt, 2F, 4JFF = 7.5 Hz, 3JFF = 23.4 Hz). 13C NMR (100 MHz, 
DMSO-d6): 161.07 (d, 1JCF = 369.0 Hz), 155.80, 146.40 (m), 143.94 (m), 143.56, 
143.43, 140.71, 138.08 (m), 135.47 (m), 127.65, 126.98, 124.92, 120.12, 110.55 (m), 
66.08, 51.31 (d, 2JCF = 52.4 Hz), 46.43, 23.21. 
 
General Procedure for the Preparation of Puromycin Derivatives 2a-g (Method 1) 
After co-evaporationing with pyridine (3 x 10ml), puromycin aminonucleoside (1 eq) was 
placed in a 50 ml round bottom flask under argon and dissolved with anhydrous DMF 
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and anhydrous pyridine.  Acyl fluoride derivative 1a-g (1.01 eq) was introduced and the 
solution was stirred at room temperature for 3 hours.  After evaporation in vacuo, the 




N6,N6-dimethyladenosine 2a.  Isolated in 94% yield (468 mg) by flash chromatography 
(CH2Cl2 /MeOH, 95:5), starting from puromycin aminonucleoside (200 mg, 0.680 mmol), 
acyl fluoride 1a (342 mg, 0.686 mmol), anhydrous pyridine (1 ml), anhydrous DMF (19 
ml).  1H NMR (500 MHz, DMSO-d6): 8.50 (s, 1H), 8.33 (d, 1H, 3JHH = 6.9 Hz), 8.29 (s, 
1H), 7.92 (d, 2H, 3JHH = 7.5 Hz), 7.72 (m, 2H), 7.66 (t, 2H, 3JHH = 7.1 Hz), 7.57 (d, 1H, 
3JHH = 8.2 Hz), 7.39 – 7.46 (m, 3H), 7.33 (m, 2H), 6.23 (d, 1H, 3JHH = 4.2 Hz), 6.06 (d, 
1H, 3JHH = 1.8 Hz), 5.24 (t, 1H, 3JHH = 5.3 Hz), 4.57 (m, 2H), 4.45 (m, 1H), 4.20 (m, 3H), 
4.03 (m, 1H), 3.74 (m, 1H), 3.56 (m, 7H), 3.06 (dd, 1H, 3JHH = 3.6 Hz, 2JHH = 13.4 Hz), 
2.84 (dd, 1H, 3JHH = 11.2 Hz, 2JHH = 12.0 Hz). 13C NMR (125 MHz, DMSO-d6): 171.89, 
156.12, 154.64, 152.22, 150.03, 144.14, 144.01, 141.02, 140.99, 139.83, 138.26, 
131.69, 130.88, 130.45, 130.22, 129.32, 127.96, 127.36, 125.63, 125.55, 120.45, 
119.99, 89.79, 83.83, 73.40, 66.06, 61.29, 56.04, 55.26, 50.73, 46.87, 37.37. ESI-MS 
(ES+): m/z calcd for C36H35Cl2N7O6 731.2, found 732.6 (MH+), 754.5 (M + Na+). 
 
3’-Amino-3’-deoxy-3’-[N-(9-fluorenylmethoxycarbonyl)-L-2,4-dichlorophenylalanyl]-
N6,N6-dimethyladenosine 2b.  Isolated in 87% yield (432 mg) by flash chromatography 
(CH2Cl2 /MeOH, 95:5), starting from puromycin aminonucleoside (200 mg, 0.680 mmol), 
acyl fluoride 1b (342 mg, 0.686 mmol), anhydrous pyridine (1 ml), anhydrous DMF (19 
ml).  1H NMR (500 MHz, DMSO-d6): 8.37 (s, 1H), 8.16 (s, 1H), 7.97 (d, 1H, 3JHH = 7.6 
Hz), 7.81 (d, 2H, 3JHH = 7.5 Hz), 7.62 (d, 1H, 3JHH = 8.9 Hz), 7.58 (d, 2H, 3JHH = 7.3 Hz), 
7.49 (d, 1H, 3JHH = 2.1 Hz), 7.21 – 7.35 (m, 6H), 5.97 (d, 1H, 3JHH = 4.9 Hz), 5.92 (d, 1H, 
3JHH = 3.1 Hz), 5.13 (t, 1H, 3JHH = 5.3 Hz), 4.38 – 4.47 (m, 3H), 4.05 – 4.15 (m, 3H), 
3.88 (m, 1H), 3.38 – 3.62 (m, 8H), 3.09 (dd, 1H, 3JHH = 5.2 Hz, 2JHH = 14.0 Hz), 2.88 
(dd, 1H, 3JHH = 9.8 Hz, 2JHH = 14.0 Hz). 13C NMR (125 MHz, CDCl3): 171.36, 156.04, 
154.64, 152.21, 150.05, 144.11, 144.04, 141.03, 141.02, 138.26, 134.78, 133.35, 
133.09, 132.27, 129.27, 128.90, 127.99, 127.64, 127.39, 125.63, 125.59, 120.46, 
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119.98, 89.58, 83.63, 73.35, 66.17, 61.27, 55.27, 54.30, 50.78, 46.87, 35.34. ESI-MS 
(ES+): m/z calcd for C36H35Cl2N7O6 731.2, found 732.6 (MH+), 754.6 (M + Na+). 
 
3’-Amino-3’-deoxy-3’-[N-(9-fluorenylmethoxycarbonyl)-L-2-nitrophenylalanyl]-N6,N6-
dimethyladenosine 2c.  Isolated in 99% yield (480 mg) by flash chromatography (CH2Cl2 
/MeOH, 95:5), starting from puromycin aminonucleoside (200 mg, 0.680 mmol), acyl 
fluoride 1c (298 mg, 0.686 mmol), anhydrous pyridine (1 ml), anhydrous DMF (19 ml).  
1H NMR (500 MHz, DMSO-d6): 8.44 (s, 1H), 8.24 (s, 1H), 8.02 (d, 1H, 3JHH = 7.7 Hz), 
7.98 (d, 1H, 3JHH = 8.0 Hz), 7.88 (d, 2H, 3JHH = 7.4 Hz), 7.71 (d, 1H, 3JHH = 8.8 Hz), 7.30 
– 7.66 (m, 9H), 6.03 (d, 1H, 3JHH = 4.9 Hz), 5.98 (d, 1H, 3JHH = 3.1 Hz), 5.18 (t, 1H, 3JHH 
= 5.4 Hz), 4.45 – 4.59 (m, 3H), 4.11 – 4.22 (m, 3H), 3.92 (m, 1H), 3.44 – 3.68 (m, 8H), 
3.37 (dd, 1H, 3JHH = 5.3 Hz, 2JHH = 14.1 Hz), 3.15 (dd, 1H, 3JHH = 9.6 Hz, 2JHH = 13.9 
Hz). 13C NMR (125 MHz, DMSO-d6): 171.40, 156.07, 154.67, 152.22, 150.08, 149.69, 
144.08, 141.05, 141.02, 138.28, 133.42, 132.86, 132.68, 129.28, 128.38, 128.00, 
127.42, 125.66, 125.69, 124.94, 120.45, 120.02, 89.59, 83.73, 73.39, 66.20, 61.34, 




dimethyladenosine 2d.  Isolated in 97% yield (450 mg) by flash chromatography 
(CH2Cl2 /MeOH, 95:5), starting from puromycin aminonucleoside (200 mg, 0.680 mmol), 
acyl fluoride 1d (280 mg, 0.686 mmol), anhydrous pyridine (1 ml), anhydrous DMF (19 
ml).  1H NMR (500 MHz, DMSO-d6): 8.43 (s, 1H), 8.22 (s, 1H), 8.06 (d, 1H, 3JHH = 7.7 
Hz), 7.86 (d, 2H, 3JHH = 7.5 Hz), 7.63 (m, 2H), 7.39 (t, 1H, 3JHH = 7.4 Hz), 7.23 – 7.35 
(m, 6H), 7.11 (t, 1H, 3JHH = 9.5 Hz), 7.06 (t, 1H, 3JHH = 7.4 Hz), 6.03 (sbr, 1H), 5.97 (d, 
1H, 3JHH = 3.1 Hz), 5.16 (t, 1H, 3JHH = 5.3 Hz), 4.42 – 4.51 (m, 3H), 4.10 – 4.22 (m, 3H), 
3.92 (m, 1H), 3.43 – 3.67 (m, 8H), 3.08 (dd, 1H, 3JHH = 5.4 Hz, 2JHH = 14.0 Hz), 2.88 
(dd, 1H, 3JHH = 9.7 Hz, 2JHH = 14.0 Hz). 19F NMR (376 MHz, DMSO-d6): -117.62 (s, 1F).  
13C NMR (125 MHz, DMSO-d6): 171.60, 162.65, 161.13 (d, 1JCF = 244.2 Hz), 156.02, 
154.65, 152.20, 150.06, 144.10, 144.09, 141.02, 141.00, 138.25, 131.96 (d, 3JCF = 4.3 
Hz), 129.27, 128.83 (d, 3JCF = 8.0 Hz), 127.98, 127.63, 127.42, 127.40, 125.70, 125.59, 
124.80 (d, 2JCF = 15.7 Hz), 124.39 (sbr), 121.73, 120.43, 120.37, 120.00, 115.33 (d, 2JCF 
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= 21.9 Hz), 89.59, 83.68, 73.39, 66.16, 61.29, 55.26, 54.98, 50.76, 46.89, 36.12, 31.46, 




dimethyladenosine 2e.  Isolated in 98% yield (470 mg) by flash chromatography (CH2Cl2 
/MeOH, 95:5), starting from puromycin aminonucleoside (200 mg, 0.680 mmol), acyl 
fluoride 1e (292 mg, 0.686 mmol), anhydrous pyridine (1 ml), anhydrous DMF (19 ml).  
1H NMR (400 MHz, DMSO-d6): 8.47 (s, 1H), 8.27 (d, 1H, 3JHH = 7.0 Hz), 8.25 (s, 1H), 
7.88 (d, 2H, 3JHH = 7.5 Hz), 7.69 (d, 1H, 3JHH = 8.8 Hz), 7.63 (d, 2H, 3JHH = 6.8 Hz), 7.20 
– 7.47 (m, 7H), 6.20 (d, 1H, 3JHH = 4.2 Hz), 6.03 (s, 1H), 5.22 (t, 1H, 3JHH = 5.3 Hz), 4.53 
(m, 1H), 4.39 – 4.45 (m, 2H), 4.11 – 4.19 (m, 3H), 3.98 (m, 1H), 3.42 (m, 8H), 3.01 (dd, 
1H, 3JHH = 3.9 Hz, 2JHH = 13.5 Hz), 2.80 (m, 1H). 19F NMR (376 MHz, DMSO-d6): -
119.53 (d, 1F, 3JFF = 22.5 Hz), -142.24 (d, 1F, 3JFF = 22.5 Hz). 13C NMR (125 MHz, 
DMSO-d6): 171.59, 155.74, 154.24, 151.85, 149.63, 148.92 (dd, 2JCF = 12.8 Hz, 1JCF = 
244.9 Hz), 148.29 (dd, 2JCF = 12.6 Hz, 1JCF = 244.7 Hz), 143.75, 143.64, 140.65, 
140.62, 137.88, 137.91 (m), 127.60, 126.96, 126.13 (m), 125.27, 125.19, 120.08, 
119.60, 118.17 (d, 2JCF = 16.9 Hz), 116.85 (d, 2JCF = 16.8 Hz), 89.42, 83.41, 73.04, 
65.66, 60.87, 55.78, 50.29, 46.48, 37.03. ESI-MS (ES+): m/z calcd for 
C36H35F2N7O6 699.2, found 700.2 (MH+). 
 
3’-Amino-3’-deoxy-3’-[N-(9-fluorenylmethoxycarbonyl)-L-2-trifluoromethylphenylalanyl]-
N6,N6-dimethyladenosine 2f.  Isolated in 98% yield (490 mg) by flash chromatography 
(CH2Cl2 /MeOH, 95:5), starting from puromycin aminonucleoside (200 mg, 0.680 mmol), 
acyl fluoride 1f (314 mg, 0.686 mmol), anhydrous pyridine (1 ml), anhydrous DMF (19 
ml).  1H NMR (400 MHz, DMSO-d6): 8.46 (s, 1H), 8.24 (s, 1H), 8.05 (d, 1H, 3JHH = 7.3 
Hz), 7.90 (d, 2H, 3JHH = 7.5 Hz), 7.81 (d, 1H, 3JHH = 8.9 Hz), 7.69 (d, 3H, 3JHH = 7.4 Hz), 
7.30 – 7.55 (m, 7H), 6.07 (d, 1H, 3JHH = 4.5 Hz), 6.00 (d, 1H, 3JHH = 2.6 Hz), 5.22 (t, 1H, 
3JHH = 5.1 Hz), 4.45 – 4.54 (m, 3H), 4.15 – 4.21 (m, 3H), 3.95 (m, 1H), 3.41 – 3.69 (m, 
8H), 3.28 (dd, 1H, 3JHH = 4.5 Hz, 2JHH = 14.0 Hz), 3.01 (dd, 1H, 3JHH = 9.9 Hz, 2JHH = 
13.7 Hz). 19F NMR (376 MHz, DMSO-d6): -57.99 (s, 3F). 13C NMR (100 MHz, DMSO-
d6): 171.10, 155.66, 154.24, 151.84, 149.65, 143.72, 143.69, 140.65, 137.90, 136.08, 
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132.04, 131.70, 127.64, 127.49 (q, 2JCF = 29.1 Hz), 127.04, 125.79 (q, 3JCF = 5.1 Hz), 
125.28, 124.55 (q, 1JCF = 273.7 Hz), 120.10, 119.58, 89.22, 83.23, 73.00, 65.82, 60.85, 




dimethyladenosine 2g.  Isolated in 87% yield (450 mg) by flash chromatography 
(CH2Cl2 /MeOH, 95:5), starting from puromycin aminonucleoside (200 mg, 0.680 mmol), 
acyl fluoride 1g (328 mg, 0.686 mmol), anhydrous pyridine (1 ml), anhydrous DMF (19 
ml).  1H NMR (400 MHz, DMSO-d6): 8.44 (s, 1H), 8.28 (d, 1H, 3JHH = 7.6 Hz), 8.24 (s, 
1H), 7.89 (d, 2H, 3JHH = 7.5 Hz), 7.65 – 7.76 (m, 3H), 7.40 – 7.44 (m, 2H), 7.32 (t, 2H, 
3JHH = 7.4 Hz), 5.96 (d, 1H, 3JHH = 3.3 Hz), 5.94 (d, 1H, 3JHH = 4.9 Hz), 5.22 (t, 1H, 3JHH 
= 5.3 Hz), 4.41 – 4.53 (m, 3H), 4.27 – 4.33 (m, 1H), 4.14 – 4.19 (m, 2H), 3.93 – 3.95 (m, 
1H), 3.42 – 4.69 (m, 8H), 3.17 (dd, 1H, 3JHH = 6.9 Hz, 2JHH = 13.9 Hz), 2.99 (dd, 1H, 
3JHH = 7.3 Hz, 2JHH = 13.5 Hz). 19F NMR (376 MHz, DMSO-d6): -141.50 (dd, 2F, 4JFF = 
7.4 Hz, 3JFF = 23.9 Hz), -157.45 (t, 1F, 3JFF = 22.2 Hz), -163.41 (dt, 2F, 4JFF = 6.7 Hz, 
3JFF = 23.2 Hz). 13C NMR (100 MHz, DMSO-d6): 172.77, 169.97, 155.56, 154.23, 
151.84, 149.69, 146.36 (m), 143.93 (m), 143.69, 143.65, 140.67, 140.64, 137.80, 
135.36 (m), 127.64, 127.61, 127.02, 126.99, 125.27, 125.21, 120.09, 120.06, 119.57, 
111.27 (m), 88.97, 82.92, 72.96, 65.92, 60.77, 53.27, 50.55, 46.48, 25.83, 25.21. ESI-
MS (ES+): m/z calcd for C36H32F5N7O6 753.2, found 754.5 (MH+). 
 
General Procedure for the Preparation of Puromycin Derivatives 2h-j (Method 2) 
After co-evaporationing with pyridine (3 x 10ml), puromycin aminonucleoside (1 eq) was 
placed in a 50 ml round bottom flask under argon.  Anhydrous DMF, N-(9-
fluorenylmethoxycarbonyl)-amino acid (1.1 eq) and N-hydroxysuccinimide (SuOH, 1.1 
eq) were introduced and the solution was cooled to 0°C.  1-[3-(dimethylamino)propyl]-3-
ethylcarbodiimide hydrochloride (EDCI, 1 eq) was added and the solution was stirred 24 
hours at room temperature.  After evaporation in vacuo, the oily residue was purified by 




dimethyladenosine 2h.  Isolated in 87% yield (400 mg) by flash chromatography 
(CH2Cl2 /MeOH, 95:5), starting from puromycin aminonucleoside (200 mg, 0.680 mmol), 
N-(9-fluorenylmethoxycarbonyl)-4-methylphenylalanine (300 mg, 0.748 mmol), SuOH 
(86 mg, 0.748 mmol), EDCI (130 mg, 0.680 mmol), anhydrous DMF (9 ml).  1H NMR 
(400 MHz, DMSO-d6): 8.46 (s, 1H), 8.25 (s, 1H), 8.20 (d, 1H, 3JHH = 7.1 Hz), 7.88 (d, 
2H, 3JHH = 7.5 Hz), 7.64 (m, 2H), 7.41 (t, 2H, 3JHH = 7.4 Hz), 7.31 (m, 3H), 7.23 (d, 2H, 
3JHH = 7.7 Hz), 7.07 (d, 2H, 3JHH = 7.7 Hz), 6.13 (d, 1H, 3JHH = 4.4 Hz), 6.01 (d, 1H, 3JHH 
= 1.9 Hz), 5.21 (t, 1H, 3JHH = 5.3 Hz), 4.50 (m, 2H), 4.37 (m, 1H), 4.11 – 4.21 (m, 3H), 
3.96 (m, 1H), 3.47 – 3.71 (m, 8H), 2.97 (dd, 1H, 3JHH = 4.1 Hz, 2JHH = 13.4 Hz), 2.77 
(dd, 1H, 3JHH = 10.5 Hz, 2JHH = 12.0 Hz), 2.24 (s, 3H). 13C NMR (100 MHz, DMSO-d6): 
171.96, 155.70, 154.24, 151.85, 149.64, 143.75, 140.62, 137.88, 135.09, 134.91, 
129.20, 128.58, 127.59, 127.01, 125.35, 125.26, 120.06, 119.60, 89.36, 83.38, 73.02, 
65.63, 60.87, 56.14, 50.26, 46.51, 37.50. ESI-MS (ES+): m/z calcd for C37H39N7O6 
677.3, found 678.6 (MH+), 700.4 (M + Na+). 
 
3’-Amino-3’-deoxy-3’-[N-(9-fluorenylmethoxycarbonyl)-L-4-(N-terbutylmethoxycarbonyl)-
phenylalanyl]-N6,N6-dimethyladenosine 2i.  Isolated in 85% yield (450 mg) by flash 
chromatography (CH2Cl2 /MeOH, 95:5), starting from puromycin aminonucleoside (200 
mg, 0.680 mmol), N-(9-fluorenylmethoxycarbonyl)-4-(N-terbutylmethoxycarbonyl)-
phenylalanine (386 mg, 0.748 mmol), SuOH (86 mg, 0.748 mmol), EDCI (130 mg, 0.680 
mmol), anhydrous DMF (9 ml).  1H NMR (500 MHz, DMSO-d6): 9.23 (sbr, 1H), 8.45 (s, 
1H), 8.24 (s, 1H), 8.14 (d, 1H, 3JHH = 7.1 Hz), 7.87 (d, 2H, 3JHH = 7.4 Hz), 7.64 (m, 2H), 
7.55 (d, 1H, 3JHH = 8.7 Hz), 7.28 – 7.40 (m, 6H), 7.21 (d, 2H, 3JHH = 8.0 Hz), 6.10 (d, 1H, 
3JHH = 4.1 Hz), 6.01 (sbr, 1H), 5.18 (t, 1H, 3JHH = 5.0 Hz), 4.48 – 4.52 (m, 2H), 4.32 – 
4.37 (m, 1H), 4.10 – 4.22 (m, 3H), 3.97 (m, 1H), 3.37 – 3.71 (m, 8H), 2.95 (dd, 1H, 3JHH 
= 3.4 Hz, 2JHH = 13.4 Hz), 2.74 (m, 1H), 1.47 (s, 9H).  13C NMR (125 MHz, DMSO-d6): 
172.29, 162.66, 156.06, 154.67, 153.16, 152.22, 150.06, 144.17, 144.11, 141.02, 
138.27, 138.15, 131.88, 129.82, 127.93, 127.43, 127.41, 125.71, 125.59, 120.42, 
120.03, 118.22, 89.75, 83.83, 79.20, 73.42, 66.05, 61.33, 56.60, 50.73, 46.93, 37.66, 




N6,N6-dimethyladenosine 2j.  Isolated in 85% yield (422 mg) by flash chromatography 
(CH2Cl2 /MeOH, 95:5), starting from puromycin aminonucleoside (200 mg, 0.680 mmol), 
N-(9-fluorenylmethoxycarbonyl)-4-trifluoromethylphenylalanine (340 mg, 0.748 mmol), 
SuOH (86 mg, 0.748 mmol), EDCI (130 mg, 0.680 mmol), anhydrous DMF (9 ml).  1H 
NMR (400 MHz, DMSO-d6): 8.47 (s, 1H), 8.33 (d, 1H, 3JHH = 6.6 Hz), 8.25 (s, 1H), 7.88 
(d, 2H, 3JHH = 7.4 Hz), 7.72 (d, 1H, 3JHH = 8.7 Hz), 7.57 – 7.64 (m, 6H), 7.25 – 7.50 (m, 
4H), 6.20 (sbr, 1H), 6.02 (s, 1H), 5.77 (s, 1H), 5.22 (m, 1H), 4.44 (m, 3H), 4.11 – 4.19 
(m, 2H), 3.97 (m, 1H), 3.48 – 3.71 (m, 8H), 3.10 – 3.28 (m, 1H), 2.88 – 2.94 (m, 1H). 19F 
NMR (376 MHz, DMSO-d6): -60.75 (s, 3F).  13C NMR (100 MHz, DMSO-d6): 172.79, 
171.57, 155.73, 154.24, 151.85, 149.93, 143.73, 143.67, 143.04, 140.62, 137.88, 
130.15, 127.56, 126.97, 125.28, 124.81, 124.78, 124.41 (q, 1JCF = 270.1 Hz), 120.07, 
119.60, 89.39, 83.36, 73.03, 65.65, 60.85, 55.64, 54.91, 50.31, 46.58, 37.68. ESI-MS 
(ES+): m/z calcd for C37H36F3N7O6 731.2, found 732.4 (MH+). 
 
General Procedure for the Preparation of 5’-Protected Puromycin Derivatives 3a-j 
In a 25 ml round bottom flask under argon, anhydrous pyridine and anhydrous 
triethylamine (2.8 eq) were added to puromycin derivatives 2a-j (1 eq).  Dimethoxytrityl 
chloride (DmTrCl, 2.5 eq) was added and the solution was stirred at room temperature 
for 3 hours.  Methanol (10 ml) was added to quench the reaction and the solution was 
stirred at room temperature for 2 hours.  After evaporation in vacuo, the residue was 




(p,p’dimethoxytrityl)-N6,N6-dimethyladenosine 3a.  Isolated in 72% yield (250 mg) by 
flash chromatography (CH2Cl2/ MeOH, 96:4), starting from puromycin derivative 2a (245 
mg, 0.335 mmol), DmTrCl (298 mg, 0.837 mmol), anhydrous NEt3 (130 μl, 0.938 mmol), 
anhydrous pyridine (10 ml).  1H NMR (500 MHz, DMSO-d6): 8.35 (s, 1H), 8.32 (d, 1H, 
3JHH = 8.7 Hz), 8.28 (s, 1H), 7.92 (d, 2H, 3JHH = 7.5 Hz), 7.69 – 7.72 (m, 2H), 7.66 (d, 
1H, 3JHH = 7.5 Hz), 7.63 (d, 1H, 3JHH = 7.5 Hz), 7.55 (d, 1H, 3JHH = 8.1 Hz), 7.23 – 7.46 
(m, 14 H), 6.83 – 6.88 (m, 4H), 6.38 (d, 1H, 3JHH = 4.8 Hz), 6.10 (sbr, 1H), 4.82 – 4.87 
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(m, 1H), 4.65 – 4.67 (m, 1H), 4.36 – 4.45 (m, 1H), 4.13 – 4.20 (m, 4H), 3.71 (s, 3H), 
3.70 (s, 3H), 3.56 (sbr, 6H), 3.32 (m, 1H), 3.17 (dd, 1H, 3JHH = 5.3 Hz, 2JHH = 10.8 Hz), 
2.73 – 2.78 (m, 1H), 2.56 – 2.63 (m, 1H).  13C NMR (100 MHz, DMSO-d6): 172.06, 
158.36, 156.13, 154.62, 152.38, 150.05, 145.11, 144.14, 144.00, 141.02, 140.98, 
139.88, 138.07, 135.67, 135.61, 131.64, 130.85, 130.42, 130.12, 129.29, 128.15, 
128.03, 127.97, 127.35, 126.97, 125.65, 125.56, 120.46, 120.06, 113.57, 113.45, 90.45, 
85.89, 81.28, 73.06, 66.01, 63.11, 60.12, 56.06, 55.24, 50.69, 46.84, 37.51. ESI-MS 
(ES+): m/z calcd for C57H53Cl2N7O8 1033.3, found 1056.8 (M + Na+).  
 
3’-Amino-3’-deoxy-3’-[N-(9-fluorenylmethoxycarbonyl)-L-2,4-dichlorophenylalanyl]-5’-O-
(p,p’dimethoxytrityl)-N6,N6-dimethyladenosine 3b.  Isolated in 72% yield (250 mg) by 
flash chromatography (CH2Cl2/ MeOH, 96:4), starting from puromycin derivative 3a (245 
mg, 0.335 mmol), DmTrCl (298 mg, 0.837 mmol), anhydrous NEt3 (130 μl, 0.938 mmol), 
anhydrous pyridine (10 ml).  1H NMR (400 MHz, DMSO-d6): 8.17 (s, 1H), 8.11 (s, 1H), 
7.94 (d, 1H, 3JHH = 8.3 Hz), 7.76 (d, 2H, 3JHH = 7.4 Hz), 7.49 – 7.54 (m, 2H), 7.41 (d, 1H, 
4JHH = 2.0 Hz), 7.04 – 7.30 (m, 16 H), 6.69 (d, 2H, 3JHH = 5.5 Hz), 6.66 (d, 2H, 3JHH = 5.5 
Hz), 6.01 (d, 1H, 3JHH = 4.9 Hz), 5.91 (d, 1H, 3JHH = 2.3 Hz), 4.62 – 4.68 (m, 1H), 4.53 – 
4.56 (m, 1H), 4.31 – 4.37 (m, 1H), 3.96 – 4.06 (m, 4H), 3.56 (s, 6H), 3.38 (sbr, 6H), 3.14 
(m, 1H), 3.04 (dd, 1H, 3JHH = 5.0 Hz, 2JHH = 10.5 Hz), 2.87 (dd, 1H, 3JHH = 4.6 Hz, 2JHH = 
14.1 Hz), 2.73 (dd, 1H, 3JHH = 10.4 Hz, 2JHH = 14.0 Hz).  13C NMR (100 MHz, DMSO-
d6): 171.38, 158.37, 158.35, 156.04, 154.64, 152.35, 150.15, 145.11, 144.12, 144.03, 
141.04, 141.01, 138.14, 135.80, 135.69, 134.81, 133.03, 132.22, 130.09, 130.03, 
128.86, 128.10, 128.07, 127.98, 127.38, 127.26, 126.97, 125.65, 125.60, 120.46, 
120.07, 113.43, 90.00, 85.87, 81.28, 72.96, 66.16, 63.30, 60.12, 55.27, 54.19, 50.92, 




(p,p’dimethoxytrityl)-N6,N6-dimethyladenosine 3c.  Isolated in 72% yield (270 mg) by 
flash chromatography (AcOEt/Hex, 8:2), starting from puromycin derivative 2c (260 mg, 
0.366 mmol), DmTrCl (330 mg, 0.915 mmol), anhydrous NEt3 (150 μl, 1.024 mmol), 
anhydrous pyridine (12 ml).  1H NMR (400 MHz, DMSO-d6): 8.30 (s, 1H), 8.24 (s, 1H), 
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8.03 (d, 1H, 3JHH = 8.2 Hz), 7.97 (d, 1H, 3JHH = 7.9 Hz), 7.88 (d, 2H, 3JHH = 7.5 Hz), 7.70 
(d, 1H, 3JHH = 9.0 Hz), 7.63 (d, 2H, 3JHH = 7.4 Hz), 7.49 (d, 2H, 4JHH = 4.0 Hz), 7.17 – 
7.45 (m, 14H), 6.82 (d, 2H, 3JHH = 8.7 Hz), 6.81 (d, 2H, 3JHH = 8.8 Hz), 6.15 (d, 1H, 3JHH 
= 4.7 Hz), 6.03 (d, 1H, 3JHH = 2.3 Hz), 4.73 – 4.79 (m, 1H), 4.67 – 4.70 (m, 1H), 4.53 – 
4.59 (m, 1H), 4.10 – 4.16 (m, 4H), 3.69 (s, 3H), 3.68 (s, 3H), 3.46 (sbr, 6H), 3.16 – 3.26 
(m, 3H), 3.05 (dd, 1H, 3JHH = 10.2 Hz, 2JHH = 13.9 Hz).  13C NMR (100 MHz, DMSO-d6): 
171.00, 157.98, 157.96, 155.68, 154.24, 151.97, 149.76, 149.24, 144.78, 143.66, 
140.64, 140.61, 137.79, 135.43, 135.36, 132.95, 132.46, 132.35, 129.69, 129.65, 
127.95, 127.73, 127.68, 127.61, 127.03, 126.58, 125.30, 125.21, 124.58, 120.07, 
119.67, 113.05, 89.53, 85.50, 81.02, 72.57, 65.77, 63.03, 54.87, 54.49, 50.53, 46.44, 




(p,p’dimethoxytrityl)-N6,N6-dimethyladenosine 3d.  Isolated in 72% yield (300 mg) by 
flash chromatography (CH2Cl2/ MeOH, 97:3), starting from puromycin derivative 2d (260 
mg, 0.381 mmol), DmTrCl (408 mg, 1.143 mmol), anhydrous NEt3 (180 μl, 1.257 mmol), 
anhydrous pyridine (11 ml).  1H NMR (500 MHz, CDCl3): 8.29 (s, 1H), 8.23 (s, 1H), 8.12 
(d, 1H, 3JHH = 8.3 Hz), 7.88 (d, 2H, 3JHH = 7.5 Hz), 7.58 – 7.65 (m, 3H), 7.10 – 7.42 (m, 
14H), 6.98 – 7.12 (m, 3H), 6.82 (d, 2H, 3JHH = 8.7 Hz), 6.80 (d, 2H, 3JHH = 8.7 Hz), 6.13 
(d, 1H, 3JHH = 4.7 Hz), 6.03 (d, 1H, 3JHH = 2.2 Hz), 4.73 – 4.79 (m, 1H), 4.64 – 4.67 (m, 
1H), 4.42 – 4.48 (m, 1H), 4.09 – 4.19 (m, 4H), 3.68 (sbr, 6H), 3.48 (sbr, 6H), 3.25 (m, 
1H), 3.16 (dd, 1H, 3JHH = 5.0 Hz, 2JHH = 10.3 Hz), 2.93 (dd, 1H, 3JHH = 4.4 Hz, 2JHH = 
14.1 Hz), 2.78 (m, 1H). 19F NMR (376 MHz, CDCl3): -117.04 (s, 1F).  13C NMR (125 
MHz, CDCl3): 171.25, 161.27 (d, 1JCF = 245.1 Hz), 158.50, 155.96, 154.91, 151.66, 
149.76, 149.15, 144.41, 143.77, 143.65, 141.27, 141.24, 136.02, 135.70, 135.60, 
131.60 (d, 3JCF = 3.8 Hz), 130.06, 129.94, 129.47, 129.17, 128.95 (d, 3JCF = 8.8 Hz), 
128.18, 127.83, 127.72, 127.07, 126.84, 125.08, 124.37 (d, 4JCF = 2.5 Hz), 123.54 (d, 
2JCF = 15.1 Hz), 120.57, 119.97, 119.95, 115.40 (d, 2JCF = 22.6 Hz), 113.19, 91.29, 
86.49, 84.10, 74.54, 67.24, 63.58, 55.35, 55.25, 53.41, 52.69, 47.02, 32.30. ESI-MS 




(p,p’dimethoxytrityl)-N6,N6-dimethyladenosine 3e.  Isolated in 78% yield (280 mg) by 
flash chromatography (AcOEt/Hex, 7:3), starting from puromycin derivative 2e (250 mg, 
0.357 mmol), DmTrCl (320 mg, 0.893 mmol), anhydrous NEt3 (140 μl, 0.999 mmol), 
anhydrous pyridine (12 ml).  1H NMR (400 MHz, DMSO-d6): 8.32 (s, 1H), 8.27 (d, 1H, 
3JHH = 8.7 Hz), 8.24 (s, 1H), 7.88 (d, 2H, 3JHH = 7.5 Hz), 7.67 (d, 1H, 3JHH = 9.0 Hz), 7.61 
(t, 2H, 3JHH = 7.5 Hz), 7.17 – 7.44 (m, 16H), 6.83 (d, 2H, 3JHH = 8.9 Hz), 6.82 (d, 2H, 
3JHH = 8.9 Hz), 6.36 (d, 1H, 3JHH = 4.8 Hz), 6.06 (sbr, 1H), 4.77 – 4.83 (m, 1H), 4.61 – 
4.63 (m, 1H), 4.31 – 4.37 (m, 1H), 4.05 – 4.17 (m, 4H), 3.67 (s, 3H), 3.66 (s, 3H), 3.48 
(sbr, 6H), 3.29 – 3.32 (m, 1H), 3.12 (dd, 1H, 3JHH = 5.1 Hz, 2JHH = 10.6 Hz), 2.52 – 2.72 
(m, 2H). 19F NMR (376 MHz, DMSO-d6): -139.60 (d, 1F, 3JFF = 22.5 Hz), -142.29 (d, 1F, 
3JFF = 22.6 Hz). 13C NMR (100 MHz, DMSO-d6): 171.71, 157.98, 155.74, 154.24, 
151.99, 150.16 (m), 147.60 (m), 144.73, 143.75, 143.63, 140.64, 140.60, 137.68, 
135.99 (m), 135.30, 135.23, 129.73, 127.76, 127.66, 127.60, 126.98, 126.93, 126.59, 
126.10 (m), 125.27, 125.18, 120.08, 118.68, 118.10 (d, 2JCF = 16.7 Hz), 116.80 (d, 2JCF 
= 16.7 Hz), 113.08, 90.04, 85.50, 80.90, 72.69, 65.61, 62.74, 55.79, 54.85, 50.29, 
46.46, 37.19. ESI-MS (ES+): m/z calcd for C57H53F2N7O8 1001.4, found 1002.4 (MH+), 
1024.3 (M + Na+). 
 
3’-Amino-3’-deoxy-3’-[N-(9-fluorenylmethoxycarbonyl)-L-2-trifluoromethylphenylalanyl]-
5’-O-(p,p’dimethoxytrityl)-N6,N6-dimethyladenosine 3f.  Isolated in 73% yield (280 mg) 
by flash chromatography (AcOEt/Hex, 7:3), starting from puromycin derivative 2f (270 
mg, 0.368 mmol), DmTrCl (330 mg, 0.920 mmol), anhydrous NEt3 (150 μl, 1.030 mmol), 
anhydrous pyridine (12 ml).  1H NMR (400 MHz, DMSO-d6): 8.30 (s, 1H), 8.24 (s, 1H), 
8.03 (d, 1H, 3JHH = 8.1 Hz), 7.89 (d, 2H, 3JHH = 7.5 Hz), 7.75 (d, 1H, 3JHH = 9.1 Hz), 7.65 
– 7.67 (m, 3H), 7.16 – 7.50 (m, 16 H), 6.81 (d, 2H, 3JHH = 8.5 Hz), 6.79 (d, 2H, 3JHH = 
8.6 Hz), 6.13 (d, 1H, 3JHH = 4.8 Hz), 6.04 (d, 1H, 3JHH = 2.3 Hz), 4.69 – 4.81 (m, 2H), 
4.43 – 4.49 (m, 1H), 4.08 – 4.16 (m, 4H), 3.69 (s, 6H), 3.48 (sbr, 6H), 3.16 – 3.24 (m, 
3H), 2.94 (dd, 1H, 3JHH = 10.2 Hz, 2JHH = 13.8 Hz).  19F NMR (376 MHz, DMSO-d6): -
57.95 (s, 3F). 13C NMR (100 MHz, DMSO-d6): 171.01, 157.97, 157.94, 155.65, 154.24, 
151.96, 149.78, 144.76, 143.71, 143.65, 140.65, 140.62, 137.83, 136.08, 135.43, 
135.35, 131.90, 131.74, 129.68, 129.61, 127.66, 127.63, 127.36, 126.78 (q, 2JCF = 35.2 
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Hz), 125.73 (m), 125.24, 124.51 (q, 1JCF = 273.8 Hz), 120.09, 119.67, 113.01, 89.51, 
85.46, 81.00, 72.55, 65.81, 63.04, 55.03, 54.84, 50.60, 46.45, 34.39. ESI-MS (ES+): m/z 
calcd for C58H54F3N7O8 1033.4, found 1034.4 (MH+), 1056.3 (M + Na+). 
 
3’-Amino-3’-deoxy-3’-[N-(9-fluorenylmethoxycarbonyl)-L-pentafluorophenylalanyl]-5’-O-
(p,p’dimethoxytrityl)-N6,N6-dimethyladenosine 3g.  Isolated in 40% yield (113 mg) by 
flash chromatography (CH2Cl2 /MeOH, 97:3), starting from puromycin derivative 2g (210 
mg, 0.278 mmol), DmTrCl (300 mg, 0.835 mmol), anhydrous NEt3 (130 μl, 0.917 mmol), 
anhydrous pyridine (8.5 ml).  1H NMR (400 MHz, DMSO-d6): 8.38 (sbr, 1H), 8.35 (s, 
1H), 8.30 (s, 1H), 7.95 – 7.97 (m, 3H), 7.72 – 7.75 (m, 3H), 7.25 – 7.49 (m, 10 H), 7.06 
– 7.16 (m, 2H), 6.89 (d, 2H, 3JHH = 8.7 Hz), 6.88 (d, 2H, 3JHH = 8.7 Hz), 6.09 (d, 1H, 3JHH 
= 1.9 Hz), 6.08 (d, 1H, 3JHH = 4.0 Hz), 4.58 (m, 1H), 4.12 – 4.34 (m, 6H), 3.76 (s, 6H), 
3.48 (sbr, 6H), 3.25 – 3.37 (m, 2H), 3.17 (dd, 1H, 3JHH = 5.4 Hz, 2JHH = 14.1 Hz), 2.98 
(dd, 1H, 3JHH = 8.7 Hz, 2JHH = 14.0 Hz).  19F NMR (376 MHz, DMSO-d6): -141.46 (dd, 
2F, 4JFF = 7.5 Hz, 3JFF = 24.2 Hz), -157.36 (t, 1F, 3JFF = 21.6 Hz), -163.44 (dt, 2F, 4JFF = 
7.2 Hz, 3JFF = 22.7 Hz). 13C NMR (100 MHz, DMSO-d6): 169.91, 157.97, 157.84, 
155.65, 154.26, 151.96, 149.82, 144.90, 144.71, 143.96 (m), 143.65, 143.61, 143.56, 
140.66, 140.61, 137.80, 135.44, 135.37, 135.19 (m), 129.70, 129.63, 127.69, 127.64, 
127.60, 127.48, 120.05, 119.69, 113.02, 112.82, 89.34, 85.52, 80.78, 72.44, 65.92, 
63.13, 54.88, 53.16, 51.02, 46.46. ESI-MS (ES+): m/z calcd for C57H50F5N7O8 1055.4, 
found 1056.9 (MH+), 1078.5 (M + Na+). 
 
3’-Amino-3’-deoxy-3’-[N-(9-fluorenylmethoxycarbonyl)-L-4-methylphenylalanyl]-5’-O-
(p,p’dimethoxytrityl)-N6,N6-dimethyladenosine 3h.  Isolated in 79% yield (240 mg) by 
flash chromatography (AcOEt/Hex, 7:3), starting from puromycin derivative 2h (210 mg, 
0.309 mmol), DmTrCl (280 mg, 0.772 mmol), anhydrous NEt3 (120 μl, 0.865 mmol), 
anhydrous pyridine (10 ml).  1H NMR (500 MHz, DMSO-d6): 8.30 (s, 1H), 8.24 (s, 1H), 
8.17 (d, 1H, 3JHH = 8.5 Hz), 7.87 (d, 2H, 3JHH = 7.5 Hz), 7.64 (d, 1H, 3JHH = 7.5 Hz), 7.62 
(d, 1H, 3JHH = 7.5 Hz), 7.56 (d, 1H, 3JHH = 8.8 Hz), 7.17 – 7.42 (m, 15H), 7.03 (d, 2H, 
3JHH = 8.4 Hz), 6.80 – 6.83 (m, 4H), 6.22 (d, 1H, 3JHH = 4.8 Hz), 6.05 (d, 1H, 3JHH = 1.8 
Hz), 4.76 – 4.81 (m, 1H), 4.62 – 4.64 (m, 1H), 4.31 – 4.36 (m, 1H), 4.08 – 4.17 (m, 4H), 
3.67 (s, 3H), 3.66 (s, 3H), 3.38 (sbr, 6H), 3.30 (m, 1H), 3.14 (dd, 1H, 3JHH = 5.2 Hz, 2JHH 
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= 10.7 Hz), 2.76 (dd, 1H, 3JHH = 3.7 Hz, 2JHH = 13.6 Hz), 2.63 (m, 1H), 2.23 (s, 3H).  13C 
NMR (125 MHz, DMSO-d6): 172.37, 158.40, 158.38, 156.09, 154.67, 152.35, 150.13, 
145.14, 144.15, 144.12, 141.02, 141.00, 138.03, 135.83, 135.70, 135.39, 135.36, 
130.11, 130.08, 129.53, 128.90, 128.11, 128.09, 127.95, 127.38, 126.97, 125.72, 
125.62, 120.41, 120.11, 113.48, 113.46, 90.25, 85.90, 81.34, 73.07, 66.01, 63.25, 
56.49, 55.27, 50.77, 46.92, 38.05, 21.02. ESI-MS (ES+): m/z calcd for 
C58H57N7O8 979.4, found 980.7 (MH+), 1002.8 (M + Na+). 
 
3’-Amino-3’-deoxy-3’-[N-(9-fluorenylmethoxycarbonyl-L-4-(N-terbutylmethoxycarbonyl)-
phenylalanyl]-5’-O-(p,p’dimethoxytrityl)-N6,N6-dimethyladenosine 3i.  Isolated in 67% 
yield (280 mg) by flash chromatography (AcOEt/Hex, 7:3), starting from puromycin 
derivative 2i (300 mg, 0.385 mmol), DmTrCl (343 mg, 0.962 mmol), anhydrous NEt3 
(150 μl, 1.078 mmol), anhydrous pyridine (13 ml).  1H NMR (400 MHz, DMSO-d6): 9.26 
(s, 1H), 8.31 (s, 1H), 8.24 (s, 1H), 8.22 (d, 1H, 3JHH = 8.5 Hz), 7.88 (d, 2H, 3JHH = 7.5 
Hz), 7.65 (d, 1H, 3JHH = 7.4 Hz), 7.59 (t, 2H, 3JHH = 7.1 Hz), 7.18 – 7.44 (m, 17H), 6.82 
(d, 2H, 3JHH = 8.8 Hz), 6.81 (d, 2H, 3JHH = 8.8 Hz), 6.29 (d, 1H, 3JHH = 4.8 Hz), 6.05 (sbr, 
1H), 4.77 – 4.82 (m, 1H), 4.62 (m, 1H), 4.28 – 4.34 (m, 1H), 4.06 – 4.18 (m, 4H), 3.67 
(s, 3H), 3.66 (s, 3H), 3.48 (sbr, 6H), 3.30 (m, 1H), 3.11 – 3.15 (m, 1H), 2.54 – 2.73 (m, 
2H), 1.4 (s, 9H).  13C NMR (100 MHz, DMSO-d6): 172.06, 157.97, 155.68, 154.23, 
152.76, 151.99, 149.68, 144.74, 143.78, 143.71, 140.60, 137.69, 137.64, 135.69, 
135.25, 131.64, 129.72, 129.42, 127.76, 127.67, 127.54, 127.01, 126.58, 125.36, 
125.23, 120.04, 119.68, 117.73, 89.92, 85.49, 80.87, 78.80, 72.68, 65.59, 62.71, 56.15, 
54.91, 54.87, 50.27, 46.49, 45.64, 37.46, 28.11. ESI-MS (ES+): m/z calcd for 
C62H64N8O10 1080.4, found 1081.5 (MH+). 
 
3’-Amino-3’-deoxy-3’-[N-(9-fluorenylmethoxycarbonyl)-L-4-trifluoromethylphenylalanyl]-
5’-O-(p,p’dimethoxytrityl)-N6,N6-dimethyladenosine 3j.  Isolated in 54% yield (190 mg) 
by flash chromatography (AcOEt/Hex, 7:3), starting from puromycin derivative 2j (250 
mg, 0.341 mmol), DmTrCl (305 mg, 0.852 mmol), anhydrous NEt3 (133 μl, 0.954 mmol), 
anhydrous pyridine (11 ml).  1H NMR (400 MHz, DMSO-d6): 8.34 (sbr, 1H), 8.32 (s, 1H), 
8.23 (s, 1H), 7.87 (d, 2H, 3JHH = 7.5 Hz), 7.70 (d, 1H, 3JHH = 9.0 Hz), 7.54 – 7.63 (m, 
6H), 7.17 – 7.44 (m, 13H), 6.82 (d, 2H, 3JHH = 8.9 Hz), 6.81 (d, 2H, 3JHH = 8.9 Hz), 6.34 
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(d, 1H, 3JHH = 4.8 Hz), 6.06 (sbr, 1H), 4.78 – 4.84 (m, 1H), 4.61 – 4.63 (m, 1H), 4.38 – 
4.44 (m, 1H), 4.04 – 4.17 (m, 4H), 3.66 (s, 3H), 3.65 (s, 3H), 3.48 (sbr, 6H), 3.31 – 3.35 
(m, 1H), 3.13 (dd, 1H, 3JHH = 5.0 Hz, 2JHH = 11.2 Hz), 2.80 – 2.83 (m, 1H), 2.66 – 2.72 
(m, 1H).  19F NMR (376 MHz, DMSO-d6): -60.73 (s, 3F). 13C NMR (100 MHz, DMSO-
d6): 171.70, 157.97, 155.73, 154.24, 151.99, 149.67, 144.72, 143.72, 143.66, 143.09, 
140.62, 140.60, 137.68, 135.52, 135.24, 130.10, 129.72, 127.76, 127.67, 127.55, 
126.95, 126.93 (q, 2JCF = 31.4 Hz), 125.29, 125.19, 124.76, 124.72, 124.42 (q, 1JCF = 
271.7 Hz), 120.06, 119.68, 113.06, 90.01, 85.50, 80.86, 72.69, 65.61, 62.76, 55.60, 
54.91, 54.83, 50.34, 46.44, 37.84. ESI-MS (ES+): m/z calcd for C58H54F3N7O8 1033.4, 
found 1034.4 (MH+), 1056.4 (M + Na+). 
 
General Procedure for the Preparation of Succinate Puromycin Derivatives 4a-j 
In a 10 ml round bottom flask under argon, anhydrous pyridine and succinic anhydride 
(3.0 eq) were added to the 5’-protected puromycin derivatives 3a-j (1 eq).  4-
(dimethylamino)-pyridine (DMAP, 0.5 eq) was added and the solution was stirred 
overnight at room temperature.  Methanol (3 ml) was added and the solution was stirred 
at room temperature for 1 hour to quench the reaction.  After evaporation in vacuo, the 
residue was purified by preparative TLC plate to produce the corresponding 2’-
succinate puromycin derivatives 4a-j. 
 
3’-Amino-3’-deoxy-3’-[N-(9-fluorenylmethoxycarbonyl)-L-3,4-dichlorophenylalanyl]-5’-O-
(p,p’dimethoxytrityl)-N6,N6-dimethyladenosine-2’-O-succinate 4a.  Isolated in 55% yield 
(152 mg) by preparative TLC plate (CH2Cl2/MeOH, 90:10), starting from 5’-protected 
puromycin derivative 3a (250 mg, 0.241 mmol), succinic anhydride (73 mg, 0.723 
mmol), DMAP (15 mg, 0.120 mmol), anhydrous pyridine (2.5 ml).  1H NMR (400 MHz, 
DMSO-d6): 8.58 (d, 1H, 3JHH = 4.2 Hz), 8.37 (d, 1H, 3JHH = 8.4 Hz), 8.31 (s, 1H), 8.23 (s, 
1H), 7.87 (d, 2H, 3JHH = 7.5 Hz), 7.59 – 7.61 (m, 2H), 7.51 (d, 1H, 3JHH = 8.2 Hz), 7.16 – 
7.42 (m, 15H), 6.82 – 6.78 (m, 4H), 6.20 (d, 1H, 3JHH = 2.9 Hz), 5.87 (m, 1H), 5.11 (m, 
1H), 4.19 – 4.27 (m, 6H), 3.67 (s, 6H), 3.56 (sbr, 6H), 3.14 – 3.26 (m, 2H), 2.63 – 2.76 
(m, 6H).  13C NMR (100 MHz, DMSO-d6): 172.59, 171.50, 171.25, 157.99, 155.76, 
154.27, 152.11, 149.74, 149.60, 144.68, 143.85, 143.49, 140.63, 139.30, 138.52, 
136.12, 135.33, 135.17, 131.18, 130.57, 130.14, 129.66, 129.02, 128.90, 127.74, 
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127.61, 127.00, 126.60, 125.19, 123.90, 120.08, 119.61, 113.04, 87.11, 85.44, 80.65, 
73.70, 65.66, 62.77, 55.69, 54.87, 51.37, 49.62, 46.47, 35.76, 28.55. ESI-MS (ES-): m/z 
calcd for C61H57Cl2N7O11 1135.0, found 1134.4 (M-H+). 
 
3’-Amino-3’-deoxy-3’-[N-(9-fluorenylmethoxycarbonyl)-L-2,4-dichlorophenylalanyl]-5’-O-
(p,p’dimethoxytrityl)-N6,N6-dimethyladenosine-2’-O-succinate 4b.  Isolated in 66% yield 
(138 mg) by preparative TLC plate (CH2Cl2/MeOH, 90:10), starting from 5’-protected 
puromycin derivative 3b (190 mg, 0.183 mmol), succinic anhydride (55 mg, 0.549 
mmol), DMAP (11 mg, 0.091 mmol), anhydrous pyridine (2 ml).  1H NMR (500 MHz, 
DMSO-d6): 8.59 (d, 1H, 3JHH = 4.1 Hz), 8.32 (s, 1H), 8.30 (s, 1H), 8.23 (s, 1H), 7.88 (d, 
2H, 3JHH = 7.5 Hz), 7.15 – 7.80 (m, 19H), 6.78 – 6.82 (m, 4H), 6.20 (d, 1H, 3JHH = 3.2 
Hz), 5.88 (m, 1H), 5.08 (m, 1H), 4.34 – 4.39 (m, 1H), 4.11 – 4.25 (m, 4H), 3.75 (s, 6H), 
3.43 (sbr, 6H), 3.14 (m, 1H), 3.04 (m, 1H), 2.47 – 2.74 (m, 6H).  13C NMR (125 MHz, 
DMSO-d6): 172.56, 171.11, 170.98, 158.02, 157.98, 155.64, 154.29, 152.09, 149.80, 
149.56, 144.68, 143.87, 143.53, 140.65, 138.41, 136.14, 135.41, 135.25, 134.39, 
134.33, 132.53, 131.91, 129.69, 129.61, 128.51, 127.71, 127.65, 127.61, 127.59, 
126.99, 126.85, 126.60, 125.23, 125.18, 123.90, 120.07, 119.63, 113.04, 86.84, 85.44, 
80.56, 73.54, 65.72, 62.84, 54.91, 53.66, 51.35, 49.56, 46.50, 34.61, 28.54. ESI-MS 
(ES-): m/z calcd for C61H57Cl2N7O11 1135.0, found 1134.4 (M-H+). 
 
3’-Amino-3’-deoxy-3’-[N-(9-fluorenylmethoxycarbonyl)-L-2-nitrophenylalanyl]-5’-O-
(p,p’dimethoxytrityl)-N6,N6-dimethyladenosine-2’-O-succinate 4c.  Isolated in 79% yield 
(208 mg) by preparative TLC plate (CH2Cl2/MeOH, 90:10), starting from 5’-protected 
puromycin derivative 3c (240 mg, 0.237 mmol), succinic anhydride (72 mg, 0.711 
mmol), DMAP (15 mg, 0.118 mmol), anhydrous pyridine (2.4 ml).  1H NMR (400 MHz, 
DMSO-d6): 8.59 (sbr, 1H), 8.34 (d, 1H, 3JHH = 8.2 Hz), 8.28 (s, 1H), 8.23 (s, 1H), 7.96 – 
7.98 (m, 1H), 7.89 (d, 2H, 3JHH = 7.5 Hz), 7.63 – 7.66 (m, 2H), 7.08 – 7.53 (m, 17H), 
6.78 – 6.82 (m, 4H), 6.19 (d, 1H, 3JHH = 3.0 Hz), 5.85 – 5.88 (m, 1H), 5.02 – 5.07 (m, 
1H), 4.43 – 4.49 (m, 1H), 4.07 – 4.14 (m, 4H), 3.74 (s, 6H), 3.36 (sbr, 6H), 3.05 – 3.24 
(m, 2H), 2.45 – 2.77 (m, 6H).  13C NMR (100 MHz, DMSO-d6): 173.56, 171.25, 171.05, 
157.98, 157.95, 155.62, 154.25, 152.08, 149.73, 149.00, 144.70, 143.81, 143.54, 
140.62, 138.35, 136.12, 135.37, 135.25, 132.98, 132.60, 132.35, 132.98, 132.60, 
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132.35, 129.68, 129.59, 127.72, 127.62, 127.03, 125.26, 124.64, 120.06, 119.60, 
113.02, 86.76, 85.41, 80.67, 73.53, 65.73, 62.81, 54.88, 49.44, 46.45, 34.37, 28.74. 
ESI-MS (ES-): m/z calcd for C61H58N8O13 1111.1, found 1110.3 (M-H+). 
 
3’-Amino-3’-deoxy-3’-[N-(9-fluorenylmethoxycarbonyl)-L-2-fluorophenylalanyl]-5’-O-
(p,p’dimethoxytrityl)-N6,N6-dimethyladenosine-2’-O-succinate 4d.  Isolated in 63% yield 
(210 mg) by preparative TLC plate (CH2Cl2/MeOH, 90:10), starting from 5’-protected 
puromycin derivative 3d (300 mg, 0.304 mmol), succinic anhydride (90 mg, 0.912 
mmol), DMAP (20 mg, 0.152 mmol), anhydrous pyridine (3 ml).  1H NMR (400 MHz, 
DMSO-d6): 8.58 (d, 1H, 3JHH = 3.9 Hz), 8.33 (d, 1H, 3JHH = 8.4 Hz), 8.29 (s, 1H), 8.22 (s, 
1H), 7.88 (d, 2H, 3JHH = 7.5 Hz), 7.78 – 7.82 (m, 1H), 7.63 – 7.69 (m, 3H), 7.18 – 7.42 
(m, 14H), 7.08 – 7.13 (m, 1H), 6.94 – 6.98 (m, 1H), 6.77 – 6.82 (m, 4H), 6.20 (d, 1H, 
3JHH = 3.0 Hz), 5.86 – 5.88 (m, 1H), 5.04 – 5.09 (m, 1H), 4.33 – 4.38 (m, 1H), 4.08 – 
4.17 (m, 4H), 3.73 (s, 6H), 3.46 (sbr, 6H), 2.79 – 2.94 (m, 2H), 2.56 – 2.69 (m, 2H), 2.47 
– 2.54 (m, 4H). 19F NMR (376 MHz, DMSO-d6): -117.49 (s, 1F).  13C NMR (100 MHz, 
DMSO-d6): 172.57, 171.26, 171.12, 160.67 (d, 1JCF = 245.1 Hz), 158.01, 157.98, 
155.63, 154.27, 152.09, 149.77, 149.53, 144.70, 143.83, 143.57, 140.62, 138.41, 
136.20, 135.40, 135.25, 131.46 (d, 3JCF = 3.8 Hz), 129.70, 129.60, 128.45 (d, 3JCF = 8.8 
Hz), 127.71, 127.65, 127.61, 127.02, 126.59, 125.26, 124.33 (d, 2JCF = 15.1 Hz), 
123.92, 120.05, 119.62, 114.93 (d, 2JCF = 22.6 Hz), 113.03, 86.85, 85.42, 80.62, 73.56, 
65.71, 62.89, 54.89, 51.36, 49.55, 46.49, 30.83, 28.54. ESI-MS (ES-): m/z calcd for 
C61H58FN7O11 1084.1, found 1083.1 (M-H+). 
 
3’-Amino-3’-deoxy-3’-[N-(9-fluorenylmethoxycarbonyl)-L-3,4-difluorophenylalanyl]-5’-O-
(p,p’dimethoxytrityl)-N6,N6-dimethyladenosine-2’-O-succinate 4e.  Isolated in 85% yield 
(235 mg) by preparative TLC plate (CH2Cl2/MeOH, 90:10), starting from 5’-protected 
puromycin derivative 3e (250 mg, 0.249 mmol), succinic anhydride (75 mg, 0.747 
mmol), DMAP (15 mg, 0.124 mmol), anhydrous pyridine (2.5 ml).  1H NMR (400 MHz, 
DMSO-d6): 8.58 (d, 1H, 3JHH = 4.1 Hz), 8.39 (d, 1H, 3JHH = 8.5 Hz), 8.31 (s, 1H), 8.23 (s, 
1H), 7.88 (d, 2H, 3JHH = 7.5 Hz), 7.77 – 7.81 (m, 1H), 7.60 – 7.63 (m, 2H), 7.08 – 7.42 
(m, 16H), 6.78 – 6.81 (m, 4H), 6.21 (d, 1H, 3JHH = 2.6 Hz), 5.85 – 5.88 (m, 1H), 5.09 – 
5.15 (m, 1H), 4.13 – 4.29 (m, 5H), 3.74 (s, 6H), 3.49 (sbr, 6H), 3.13 – 3.24 (m, 2H), 2.58 
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– 2.79 (m, 6H). 19F NMR (376 MHz, DMSO-d6): -139.40 (d, 1F, 3JFF = 22.6 Hz), -142.13 
(d, 1F, 3JFF = 22.5 Hz).  13C NMR (100 MHz, DMSO-d6): 172.62, 171.64, 171.36, 
157.98, 155.74, 154.26, 152.11, 150.19 (m), 149.60, 147.32 (m), 144.69, 143.85, 
143.51, 140.63, 138.48, 136.12, 135.85 (m), 135.31, 135.17, 129.69, 129.63, 127.73, 
127.60, 126.98, 126.94, 126.58, 125.96 (m), 125.21, 123.90, 120.07, 119.63, 118.11 (d, 
2JCF = 16.9 Hz), 116.89 (d, 2JCF = 16.6 Hz), 113.03, 87.16, 85.43, 80.66, 73.73, 65.65, 
62.68, 55.98, 54.86, 51.35, 49.56, 46.46, 36.62, 28.72. ESI-MS (ES-): m/z calcd for 
C61H57F2N7O11 1102.1, found 1101.2 (M-H+). 
 
3’-Amino-3’-deoxy-3’-[N-(9-fluorenylmethoxycarbonyl)-L-2-trifluoromethylphenylalanyl]-
5’-O-(p,p’dimethoxytrityl)-N6,N6-dimethyladenosine-2’-O-succinate 4f.  Isolated in 80% 
yield (220 mg) by preparative TLC plate (CH2Cl2/MeOH, 90:10), starting from 5’-
protected puromycin derivative 3f (250 mg, 0.241 mmol), succinic anhydride (72 mg, 
0.723 mmol), DMAP (15 mg, 0.120 mmol), anhydrous pyridine (2.4 ml).  1H NMR (400 
MHz, DMSO-d6): 8.58 (d, 1H, 3JHH = 4.1 Hz), 8.35 (d, 1H, 3JHH = 8.4 Hz), 8.29 (s, 1H), 
8.23 (s, 1H), 7.89 (d, 2H, 3JHH = 7.5 Hz), 7.78 – 7.82 (m, 1H), 7.60 – 7.75 (m, 3H), 7.02 
– 7.55 (m, 16H), 6.84 – 6.89 (m, 4H), 6.20 (d, 1H, 3JHH = 2.8 Hz), 5.88 (dd, 1H, 3JHH = 
2.9 Hz, 2JHH = 6.5 Hz), 5.07 – 5.12 (m, 1H), 4.33 – 4.39 (m, 1H), 4.01 – 4.19 (m, 4H), 
3.74 (s, 6H), 3.48 (sbr, 6H), 2.95 – 3.21 (m, 2H), 2.45 – 2.69 (m, 6H).  19F NMR (376 
MHz, DMSO-d6): -58.10 (s, 3F).  13C NMR (100 MHz, DMSO-d6): 173.61, 171.26, 
171.14, 157.98, 157.94, 155.60, 154.25, 152.08, 149.71, 149.60, 144.71, 143.86, 
143.53, 140.64, 138.39, 136.12, 136.01, 135.36, 135.25, 131.84, 131.72, 129.66, 
129.56, 127.68, 127.61, 127.31, 126.56 (q, 2JCF = 35.2 Hz), 125.85 (m), 125.34, 125.25, 
124.32 (q, 1JCF = 273.8 Hz), 123.90, 120.06, 119.62, 113.00, 86.90, 85.39, 80.55, 73.59, 
65.76, 62.78, 54.91, 49.52, 46.46, 33.95, 28.81. ESI-MS (ES-): m/z calcd for 
C62H58F3N7O11 1134.1, found 1133.2 (M-H+). 
 
3’-Amino-3’-deoxy-3’-[N-(9-fluorenylmethoxycarbonyl)-L-pentafluorophenylalanyl]-5’-O-
(p,p’dimethoxytrityl)-N6,N6-dimethyladenosine-2’-O-succinate 4g.  Isolated in 62% yield 
(67 mg) by preparative TLC plate (CH2Cl2/MeOH, 90:10), starting from 5’-protected 
puromycin derivative 3g (100 mg, 0.094 mmol), succinic anhydride (30 mg, 0.282 
mmol), DMAP (6 mg, 0.047 mmol), anhydrous pyridine (1 ml).  1H NMR (400 MHz, 
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DMSO-d6): 8.67 (d, 1H, 3JHH = 3.9 Hz), 8.51 (d, 1H, 3JHH = 8.4 Hz), 8.38 (s, 1H), 8.31 (s, 
1H), 7.99 (d, 2H, 3JHH = 7.5 Hz), 7.86 – 7.92 (m, 2H), 7.73 – 7.77 (m, 2H), 7.20 – 7.54 
(m, 16H), 6.28 (d, 1H, 3JHH = 3.5 Hz), 5.97 (dd, 1H, 3JHH = 3.5 Hz, 3JHH = 6.6 Hz), 5.16 – 
5.18 (m, 1H), 4.48 – 4.50 (m, 1H), 4.21 – 4.32 (m, 4H), 3.80 (s, 6H), 3.56 (sbr, 6H), 3.03 
– 3.13 (m, 2H), 2.54 – 2.71 (m, 6H).  19F NMR (376 MHz, DMSO-d6): -141.46 (dd, 2F, 
4JFF = 7.5 Hz, 3JFF = 24.2 Hz), -157.36 (t, 1F, 3JFF = 21.6 Hz), -163.44 (dt, 2F, 4JFF = 7.2 
Hz, 3JFF = 22.7 Hz). 13C NMR (100 MHz, DMSO-d6): 172.57, 171.17, 169.95, 158.00, 
157.98, 155.65, 154.28, 152.07, 149.77, 149.58, 146.38 (m), 144.65, 143.74, 143.53, 
140.64, 138.46, 138.40 (m), 136.13, 135.38, 135.27, 129.67, 129.57, 127.62, 126.95, 
125.14, 123.90, 120.07, 119.61, 112.99, 112.74, 86.75, 85.46, 80.71, 73.49, 65.87, 
62.98, 54.89, 53.22, 51.36, 49.70, 46.46, 28.48. ESI-MS (ES-): m/z calcd for 
C61H54F5N7O11 1156.1, found 1155.1 (M-H+). 
 
3’-Amino-3’-deoxy-3’-[N-(9-fluorenylmethoxycarbonyl)-L-4-methylphenylalanyl]-5’-O-
(p,p’dimethoxytrityl)-N6,N6-dimethyladenosine-2’-O-succinate 4h.  Isolated in 78% yield 
(191 mg) by preparative TLC plate (CH2Cl2/MeOH, 90:10), starting from 5’-protected 
puromycin derivative 3h (220 mg, 0.224 mmol), succinic anhydride (68 mg, 0.672 
mmol), DMAP (14 mg, 0.112 mmol), anhydrous pyridine (2.3 ml).  1H NMR (500 MHz, 
DMSO-d6): 8.59 (d, 1H, 3JHH = 4.1 Hz), 8.35 (d, 1H, 3JHH = 8.5 Hz), 8.29 (s, 1H), 8.23 (s, 
1H), 7.87 (d, 2H, 3JHH = 7.5 Hz), 7.76 – 7.81 (m, 1H), 7.63 – 7.65 (m, 2H), 7.17 – 7.41 
(m, 15H), 7.03 (d, 2H, 3JHH = 7.8 Hz), 6.77 – 6.80 (m, 4H), 6.20 (d, 1H, 3JHH = 2.6 Hz), 
5.85 – 5.87 (m, 1H), 5.08 – 5.13 (m, 1H), 4.23 – 4.28 (m, 1H), 4.11 – 4.18 (m, 4H), 3.67 
(s, 6H), 3.42 (sbr, 6H), 3.14 – 3.23 (m, 2H), 2.58 – 2.78 (m, 6H), 2.23 (s, 3H).  13C NMR 
(125 MHz, DMSO-d6): 173.00, 172.38, 171.69, 158.39, 158.36, 156.10, 154.68, 152.47, 
150.12, 149.98, 145.08, 144.26, 143.98, 141.00, 138.79, 137.80, 136.48, 135.79, 
135.61, 135.48, 135.27, 130.08, 129.99, 129.43, 128.96, 128.09, 128.03, 127.96, 
127.93, 127.39, 126.96, 125.71, 125.67, 124.26, 120.40, 120.04, 113.43, 87.46, 85.83, 
81.09, 74.08, 66.02, 63.13, 56.66, 55.27, 51.72, 49.92, 46.91, 37.58, 29.17, 21.02. ESI-






phenylalanyl]-5’-O-(p,p’dimethoxytrityl)-N6,N6-dimethyladenosine-2’-O-succinate 4i.  
Isolated in 74% yield (212 mg) by preparative TLC plate (CH2Cl2/MeOH, 90:10), starting 
from 5’-protected puromycin derivative 3i (260 mg, 0.240 mmol), succinic anhydride (73 
mg, 0.720 mmol), DMAP (15 mg, 0.120 mmol), anhydrous pyridine (2.4 ml).  1H NMR 
(500 MHz, DMSO-d6): 9.24 (sbr, 1H), 8.58 (d, 1H, 3JHH = 4.1 Hz), 8.36 (d, 1H, 3JHH = 
8.3 Hz), 8.28 (s, 1H), 8.23 (s, 1H), 7.87 (d, 2H, 3JHH = 7.5 Hz), 7.77 – 7.81 (m, 1H), 7.61 
– 7.63 (m, 2H), 7.17 – 7.41 (m, 17H), 6.78 – 6.80 (m, 4H), 6.19 (d, 1H, 3JHH = 2.4 Hz), 
5.85 – 5.87 (m, 1H), 5.10 – 5.15 (m, 1H), 4.12 – 4.25 (m, 5H), 3.71 (s, 6H), 3.44 (sbr, 
6H), 3.13 – 3.23 (m, 2H), 2.45 – 2.74 (m, 6H), 1.47 (s, 9H).  13C NMR (125 MHz, 
DMSO-d6): 173.02, 172.47, 171.78, 158.37, 158.35, 156.10, 154.67, 153.15, 152.48, 
150.10, 149.99, 145.06, 144.28, 143.97, 140.99, 138.76, 138.15, 136.49, 135.77, 
135.59, 131.94, 130.07, 129.99, 129.73, 129.29, 128.10, 128.02, 127.94, 127.89, 
127.65, 127.43, 127.40, 126.95, 125.70, 124.27, 121.75, 120.39, 120.04, 118.21, 
113.44, 87.52, 85.84, 81.07, 79.19, 74.14, 66.03, 62.99, 56.81, 55.27, 51.71, 49.90, 




5’-O-(p,p’dimethoxytrityl)-N6,N6-dimethyladenosine-2’-O-succinate 4j.  Isolated in 71% 
yield (133 mg) by preparative TLC plate (CH2Cl2/MeOH, 90:10), starting from 5’-
protected puromycin derivative 3j (170 mg, 0.164 mmol), succinic anhydride (50 mg, 
0.492 mmol), DMAP (10 mg, 0.082 mmol), anhydrous pyridine (1.7 ml).  1H NMR (400 
MHz, DMSO-d6): 8.58 (d, 1H, 3JHH = 3.9 Hz), 8.46 (d, 1H, 3JHH = 8.4 Hz), 8.30 (s, 1H), 
8.21 (s, 1H), 7.93 – 7.95 (m, 1H), 7.87 (d, 2H, 3JHH = 7.5 Hz), 7.48 – 7.63 (m, 5H), 7.08 
– 7.41 (m, 14H), 6.78 – 6.81 (m, 4H), 6.20 (d, 1H, 3JHH = 2.4 Hz), 5.86 – 5.88 (m, 1H), 
5.12 – 5.18 (m, 1H), 4.30 – 4.35 (m, 1H), 4.05 – 4.20 (m, 4H), 3.66 (s, 6H), 3.48 (sbr, 
6H), 3.13 – 3.25 (m, 2H), 2.58 – 2.90 (m, 6H).  19F NMR (376 MHz, DMSO-d6): -60.75 
(s, 3F).  13C NMR (100 MHz, DMSO-d6): 172.64, 171.68, 171.41, 157.96, 155.75, 
154.26, 152.10, 149.68, 149.60, 144.67, 143.83, 143.53, 143.02, 140.61, 138.46, 
136.12, 135.33, 135.17, 130.02, 129.68, 129.62, 127.73, 127.61, 127.16, 126. 82 (q, 
2JCF = 31.2 Hz), 125.27, 124.84, 124.37 (q, 1JCF = 271.7 Hz), 120.04, 119.64, 113.04, 
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87.19, 85.43, 80.63, 73.75, 65.64, 62.63, 55.85, 54.84, 51.34, 49.56, 46.44, 37.29, 
28.79. ESI-MS (ES-): m/z calcd for C62H58F3N7O11 1134.1, found 1133.2 (M-H+). 
 
 
 
